Suppr超能文献

放射治疗成像基准标记物的定性评估。

Qualitative evaluation of fiducial markers for radiotherapy imaging.

作者信息

Chan Maria F, Cohen Gil'ad N, Deasy Joseph O

机构信息

Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

出版信息

Technol Cancer Res Treat. 2015 Jun;14(3):298-304. doi: 10.1177/1533034614547447. Epub 2014 Sep 16.

Abstract

PURPOSE

To evaluate visibility, artifacts, and distortions of various commercial markers in magnetic resonance imaging (MRI), computer tomography (CT), and ultrasound imaging used for radiotherapy planning and treatment guidance.

METHODS

We compare 2 solid gold markers, 4 gold coils, and 1 polymer marker from 3 vendors. Imaging modalities used were 3-T and 1.5-T GE MRIs, Siemens Sequoia 512 Ultrasound, Phillips Big Bore CT, Varian Trilogy linear accelerator (cone-beam CT [CBCT], on-board imager kilovoltage [OBI-kV], electronic portal imaging device megavoltage [EPID-MV]), and Medtronic O-ARM CBCT. Markers were imaged in a 30 × 30 × 10 cm(3) custom bolus phantom. In one experiment, Surgilube was used around the markers to reduce air gaps. Images were saved in Digital Imaging and Communications in Medicine (DICOM) format and analyzed using an in-house software. Profiles across the markers were used for objective comparison of the markers' signals. The visibility and artifacts/distortions produced by each marker were assessed qualitatively and quantitatively.

RESULTS

All markers are visible in CT, CBCT, OBI-kV, and ultrasound. Gold markers below 0.75 mm in diameter are not visible in EPID-MV images. The larger the markers, the more CT and CBCT image artifacts there are, yet the degree of the artifact depends on scan parameters and the scanner itself. Visibility of gold coils of 0.75 mm diameter or larger is comparable across all imaging modalities studied. The polymer marker causes minimal artifacts in CT and CBCT but has poor visibility in EPID-MV. Gold coils of 0.5 mm exhibit poor visibility in MRI and EPID-MV due to their small size. Gold markers are more visible in 3-T T1 gradient-recalled echo than in 1.5-T T1 fast spin-echo, depending on the scan sequence. In this study, all markers are clearly visible on ultrasound.

CONCLUSION

All gold markers are visible in CT, CBCT, kV, and ultrasound; however, only the large diameter markers are visible in MV. When MR and EPID-MV imagers are used, the selection of fiducial markers is not straightforward. For hybrid kV/MV image-guided radiotherapy imaging, larger diameter markers are suggested. If using kV imaging alone, smaller sized markers may be used in smaller sized patients in order to reduce artifacts. Only larger diameter gold markers are visible across all imaging modalities.

摘要

目的

评估用于放射治疗计划和治疗引导的各种商业标记物在磁共振成像(MRI)、计算机断层扫描(CT)和超声成像中的可视性、伪影和畸变情况。

方法

我们比较了来自3个供应商的2种实心金标记物、4种金线圈和1种聚合物标记物。使用的成像模态包括3-T和1.5-T的GE MRI、西门子Sequoia 512超声、飞利浦大孔径CT、瓦里安Trilogy直线加速器(锥形束CT [CBCT]、机载成像器千伏 [OBI-kV]、电子射野影像装置兆伏 [EPID-MV])以及美敦力O-ARM CBCT。标记物在一个30×30×10 cm³的定制团注体模中成像。在一个实验中,在标记物周围使用外科用润滑剂以减少气隙。图像以医学数字成像和通信(DICOM)格式保存,并使用内部软件进行分析。标记物的剖面用于对标记物信号进行客观比较。对每个标记物产生的可视性和伪影/畸变进行定性和定量评估。

结果

所有标记物在CT、CBCT、OBI-kV和超声中均可见。直径小于0.75 mm的金标记物在EPID-MV图像中不可见。标记物越大,CT和CBCT图像伪影越多,但其伪影程度取决于扫描参数和扫描仪本身。在所研究的所有成像模态中,直径0.75 mm及以上的金线圈的可视性相当。聚合物标记物在CT和CBCT中产生的伪影最小,但在EPID-MV中的可视性较差。0.5 mm的金线圈由于尺寸小,在MRI和EPID-MV中的可视性较差。根据扫描序列,金标记物在3-T T1梯度回波序列中比在1.5-T T1快速自旋回波序列中更易见。在本研究中,所有标记物在超声上均清晰可见。

结论

所有金标记物在CT、CBCT、千伏成像和超声中均可见;然而,只有大直径标记物在兆伏成像中可见。当使用MR和EPID-MV成像器时,基准标记物的选择并不简单。对于混合千伏/兆伏图像引导放射治疗成像,建议使用较大直径的标记物。如果仅使用千伏成像,对于体型较小的患者可使用较小尺寸的标记物以减少伪影。只有较大直径的金标记物在所有成像模态中均可见。

相似文献

1
Qualitative evaluation of fiducial markers for radiotherapy imaging.
Technol Cancer Res Treat. 2015 Jun;14(3):298-304. doi: 10.1177/1533034614547447. Epub 2014 Sep 16.
4
Fiducial markers visibility and artefacts in prostate cancer radiotherapy multi-modality imaging.
Radiat Oncol. 2019 Dec 26;14(1):237. doi: 10.1186/s13014-019-1447-1.
6
Evaluation of different fiducial markers for image-guided radiotherapy and particle therapy.
J Radiat Res. 2013 Jul;54 Suppl 1(Suppl 1):i61-8. doi: 10.1093/jrr/rrt071.
8
Low-dose megavoltage cone-beam CT for radiation therapy.
Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):552-60. doi: 10.1016/j.ijrobp.2004.10.011.

引用本文的文献

2
Smart Radiotherapy Biomaterials for Image-Guided In Situ Cancer Vaccination.
Nanomaterials (Basel). 2023 Jun 12;13(12):1844. doi: 10.3390/nano13121844.
3
A clinical study comparing polymer and gold fiducials for prostate cancer radiotherapy.
Front Oncol. 2023 Feb 1;12:1023288. doi: 10.3389/fonc.2022.1023288. eCollection 2022.
4
A liquid immunogenic fiducial eluter for image-guided radiotherapy.
Front Oncol. 2022 Dec 21;12:1020088. doi: 10.3389/fonc.2022.1020088. eCollection 2022.
5
Long-Term In Vitro Assessment of Biodegradable Radiopaque Composites for Fiducial Marker Fabrication.
Int J Mol Sci. 2022 Nov 18;23(22):14363. doi: 10.3390/ijms232214363.
7
Magnetic resonance linear accelerator technology and adaptive radiation therapy: An overview for clinicians.
CA Cancer J Clin. 2022 Jan;72(1):34-56. doi: 10.3322/caac.21707. Epub 2021 Nov 18.
8
MRI-TRUS registration methodology for TRUS-guided HDR prostate brachytherapy.
J Appl Clin Med Phys. 2021 Aug;22(8):284-294. doi: 10.1002/acm2.13292. Epub 2021 Jul 28.
10
Exploratory models comparing ethiodized oil-glue and gold fiducials for bladder radiotherapy image-guidance.
Phys Imaging Radiat Oncol. 2021 Feb 6;17:77-83. doi: 10.1016/j.phro.2021.01.008. eCollection 2021 Jan.

本文引用的文献

2
Evaluation of different fiducial markers for image-guided radiotherapy and particle therapy.
J Radiat Res. 2013 Jul;54 Suppl 1(Suppl 1):i61-8. doi: 10.1093/jrr/rrt071.
4
Effect of gold marker seeds on magnetic resonance spectroscopy of the prostate.
Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):451-8. doi: 10.1016/j.ijrobp.2011.06.2001. Epub 2012 Jan 13.
5
Fiducial markers in prostate for kV imaging: quantification of visibility and optimization of imaging conditions.
Phys Med Biol. 2012 Jan 7;57(1):155-72. doi: 10.1088/0031-9155/57/1/155. Epub 2011 Nov 30.
6
Investigation of dose perturbations and the radiographic visibility of potential fiducials for proton radiation therapy of the prostate.
Phys Med Biol. 2011 Aug 21;56(16):5287-302. doi: 10.1088/0031-9155/56/16/014. Epub 2011 Jul 28.
7
Internal fiducial markers and susceptibility effects in MRI-simulation and measurement of spatial accuracy.
Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1612-8. doi: 10.1016/j.ijrobp.2011.01.046. Epub 2011 Apr 7.
9
Image-guided radiotherapy (IGRT) for prostate cancer comparing kV imaging of fiducial markers with cone beam computed tomography (CBCT).
Int J Radiat Oncol Biol Phys. 2011 May 1;80(1):301-5. doi: 10.1016/j.ijrobp.2010.06.007. Epub 2010 Sep 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验